Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...

Revelation Biosciences (REVB) announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells exposed ...

REVB READ THE FULL REVB RESEARCH REPORT Revelation Biosciences (NASDAQ:REVB) is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of ...

Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...

The following is a summary of “Transcriptomic insights into early mechanisms underlying post-chikungunya chronic inflammatory ...

A new review highlights how gut microbiome imbalances contribute to cardiovascular disease by altering short-chain fatty ...

INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...

Anterior cruciate ligament (ACL) injuries are prevalent, with over 400 000 reconstruction surgeries globally each year.

With over half the cells in the human body being bacterial rather than human, and over 99% of the genes in the human body ...

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic SclerosisTEL AVIV, Israel, ...

Herpesvirus-encoded microRNAs (v-miRNAs) play a crucial role in modulating host cellular processes to promote viral persistence, immune evasion, and pathogenesis. These v-miRNAs function by targeting ...

Correspondence to Dr Sizheng Steven Zhao, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological ...